Director Shareholding

AstraZeneca PLC
05 May 2005

Dealing by Directors
Companies Act 1985 Sections 324/329


We hereby inform you that the interest of David R. Brennan, a Director of the
Company, in the American Depositary Shares (ADSs) of AstraZeneca PLC has changed
as detailed below.  One ADS equals one Ordinary Share.


As previously notified on 31 March 2005, Mr Brennan became unconditionally
entitled to 18,925 ADSs on the partial vesting of an award under the terms of
the AstraZeneca US Executive Performance Share Plan.  Mr Brennan has elected to
defer the value of those ADSs, less certain mandatory tax deductions, into the
AstraZeneca US Executive Deferral Plan, a unitised stock fund established in
2000, in which Mr Brennan, in common with other participating US executives, is
deemed to have a notional interest in ADSs calculated by reference to the fund
value and the closing price of AstraZeneca ADSs.  This deferral occurred on 29
April 2005, following which Mr Brennan has a notional interest in 74,073 ADSs in
the AstraZeneca US Executive Deferral Plan as at 29 April 2005 based on that
day's closing price of US$43.95.


In total, Mr Brennan now has an interest in 169,993 AstraZeneca ADSs, including
the notional interest in ADSs in the AstraZeneca US Executive Deferral Plan
referred to above.


G H R Musker
Company Secretary
5 May 2005





                      This information is provided by RNS
            The company news service from the London Stock Exchange